AstraZeneca's AZD0780 cut LDL cholesterol by 50.7% in a Phase 2b trial, with 84% of participants reaching target levels. Shares rose 1.8% after the announcement.
AstraZeneca's Enhertu showed better response rates in biliary tract cancer patients compared to Compass Therapeutics' tovecimig, which had a 17.1% response rate with chemotherapy.
OncoHelix has formed a partnership with AstraZeneca to offer liquid biopsy testing tailored for men diagnosed with prostate cancer.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.